Vanguard Portfolio Management
ZNTL icon

Vanguard Portfolio Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Vanguard Portfolio Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92M Buy
808,548
+447,948
+124% +$1.79M ﹤0.01% 2507
2026
Q1 		$844K Buy
+360,600
New +$931K ﹤0.01% 2850

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Portfolio Management's ZNTL Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Zentalis Pharmaceuticals (ZNTL) stake by 124% in Q2 2026, buying an estimated $1.79M and bringing the position to 808,548 shares worth $3.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2507.

Vanguard Portfolio Management first reported a position in ZNTL in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Vanguard Portfolio Management held 808,548 shares of Zentalis Pharmaceuticals worth $3.92M as of Q2 2026.
  • Vanguard Portfolio Management bought 447,948 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $1.79M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2507 holding.
  • Vanguard Portfolio Management first reported a position in Zentalis Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.